WFSBP 2019 Final Program

31 Tuesday, 4 June 2019 / Scientific Program WFSBP 2019 TUE aa Tuesday, 4 June 2019 T49: PSYCHOPHARMACOLOGY S-21 SYMPOSIUM 08:15–09:45 Ballroom B/C Leveraging the power of numbers in large clinical trials and population studies in mental health using government and private patient care and research networks in the US and Europe: Lessons learned, opportunities, and challenges Chair: Michael Ostacher, USA Co-Chair: Andrew Alan Nierenberg, USA 001 Extending the scope of simple, multicentre trials to include evaluation of mechanism John Geddes, United Kingdom 002 Opportunities for population-based studies in nor- dic countries based on eHealth, registries and biobanks Ole Andreassen, Norway 003 MoodNetwork: The Patient Powered Patient Cen- tered Outcomes Research Network (PCORnet) Andrew Alan Nierenberg, USA 004 Practical where it matters: How clinical trials can inform care in the US Veterans Administration Michael Ostacher, USA T7: BIPOLAR DISORDERS: BASIC/CLINICAL S-22 SYMPOSIUM 08:15–09:45 Ballroom A Cognition in Bipolar Disorder (BD): State of the art for clinicians and researchers Chair: Eduard Vieta, Spain Co-Chair: Kamilla Miskowiak, Denmark 001 Methodological recommendations for cognition trials in Bipolar Disorder (BD) Kamilla Miskowiak, Denmark 002 Consensus-based recommendations for clinicians on how to assess and address cognitive impairment in Bipolar Disorder (BD) Katherine Burdick, USA 003 General screening and precision in treatment of cognition Roger McIntyre, Canada 004 Cognition treatments in Bipolar Disorder (BD): The state of the art and novel candidate treatments Lakshmi Yatham, Canada T28: NEUROIMAGING: GENETIC, FUNCTIONAL, STRUCTURAL S-23 SYMPOSIUM 08:15–09:45 East Meeting Room 8/15 Novel insights into the neurobiology of psychosis through ultra-high field neuroimaging Chair: Sophia Frangou, USA Co-Chair: Lena Palaniyappan, Canada 001 Depth-level intracortical myelin abnormalities in psychosis Sophia Frangou, USA 002 Prognostic utility of ultra-high field imaging in first episode psychosis Lena Palaniyappan, Canada 003 Examination of the GABAergic system in schizo- phrenia implications for cognitive dysfunction Hilleke HulShoff Pol, The Netherlands 004 A multimodal magnetoencephalography, 7T fMRI, and 7T MR spectroscopy study in first episode psychosis Adrienne Lahti, USA T52: SCHIZOPHRENIA AND OTHER PSYCHOSIS: BASIC/CLINICAL S-24 SYMPOSIUM 08:15–09:45 East Meeting Room 13 Increased allostatic load and metabolic dysregulation in first-episode Schizophrenia Chair: Johann Steiner, Germany Co-Chair: Zoltan Sarnyai, Australia 001 Allostatic load is associated with psychotic symp- toms and decreases with antipsychotic treatment in patients with schizophrenia and first-episode psychosis Maximus Berger, Australia 002 Glucose homeostasis in drug-naïve first-episode schizophrenia patients Johann Steiner, Germany 003 Dysfunctional insulin signaling in drug-naïve first-episode schizophrenia: Evidence from extracellular vesicles enriched for neuronal origin Rodrigo Mansur, Canada 004 Brain bioenergetics and redox state measured by 31P magnetic resonance spectroscopy in unaffected siblings and patients with psychotic disorders Virginie-Anne Chouinard, USA